Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited has announced the oversubscription of its $3.0 million share purchase plan, raising a total of $11.1 million to fund its continued research into neurological treatments. The capital will support the enrollment of patients in the XanaMIA Phase 2b/3 trial for Alzheimer’s Disease, extending the company’s cash runway until late CY26. New shares and options will be issued upon shareholder approval at the upcoming EGM, with the options listed on the ASX for trading.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
